Chairman of the Board (COB)

Prof. Dr. Ralf Wagner

Mail

Prof. Dr. Ralf Wagner joined Lophius in January 2013 as CEO. Since June 2014, Ralf is chairing the Lophius supervisory board to coordinate strategic activities and support the companies further development.

Prior to that, he served almost 13 years as CEO of GENEART AG, a German biotech company, which he founded in 1999 as spin-off of his research group at the University of Regensburg. Under his leadership, GENEART went public in 2006 at the Frankfurt stock exchange and was acquired by Life Technologies in 2010. As CEO and VP Synthetic Biology, he also coordinated the integration activities of the Regensburg based GENEART into the US Company.

Ralf is also Professor for Medical Microbiology and Gene Therapy and member of the Medical Faculty of the University of Regensburg. Beside his management and scientific skills, he brings an excellent professional network of partners in academic research, pharma and biotech industry as well as financing.


Member of the Board

Dr. Manfred Baier

Dr. Manfred Baier has more than 30 years’ experience in the diagnostic industry, most recently as Head of Roche Applied Science. In addition, at Roche, he previously held several leadership positions, including General Manager for Sales and Head of various business areas.

Today, Dr. Manfred Baier is a member of the Board of Directors or Advisory Board of numerous life science companies in Germany, Sweden and the United Kingdom.

He holds a Diploma in chemistry and gained his PhD in biochemistry at the University of Stuttgart.


Robert Silverman

Member of the board

Robert J. Silverman

Robert J. Silverman is a director and strategic advisor to the company. He served as the CEO of mtm laboratories AG, an in vitro diagnostics company that developed and commercialized a portfolio of products for the early detection and diagnosis of cervical cancer.

Mr. Silverman was instrumental in raising capital and building mtm laboratories into a global, fully-integrated commercial business. He led the company to a $240 Million exit to Roche Diagnostics. Prior to leading mtm laboratories, he held senior executive positions at Viacell, Cytyc Corporation, Pasteur Merieux and Abbott Laboratories Pharmaceuticals.

He earned his Master's degree in Marketing and Finance from the Kellogg Graduate School of Management at Northwestern University. Bob received his B.S. degree in Pharmacy from the University of Michigan. He currently works with several companies and venture groups in a Board and Advisory capacity.


Member of the Board

Thomas Hartwig

Thomas Hartwig is Managing Director of VRD GmbH, a family office with an investment focus in sustainable industries. He has more than 25 years of industry experience from his roles as CFO at Sartorius AG, an international pharmaceutical and laboratory equipment supplier, as well as at EnBW Kraftwerke AG.

Furthermore, he is member of several supervisory boards and holds a Diploma in business administration.


Member of the Board

Monika Steger

Monika Steger is Investment Director and proxy holder at Bayern Kapital, the venture capital organisation of the State of Bavaria.

Bayern Kapital provides equity capital financing for the founders of young innovative technology companies in Bavaria and presently manages eleven investment funds with a total volume of around €340m.

Ms. Steger is responsible for the management of the Bavarian Growth Fund (“Wachstumsfonds Bayern”) which supports companies during their growth phase to gain access to the required capital. She has in-depth experience in venture capital as well as in the banking industry and holds a Diploma in business administration.

www.bayernkapital.de


This function requires IE9 or higher.
You can update your browser under:
http://windows.microsoft.com/de-DE/internet-explorer/download-ie